ENANTA PHARMACEUTICALS ($ENTA) posted quarterly earnings results for Q4 2026 on Monday, November 16th. The company reported earnings of -$0.81 per share, missing estimates of -$0.80 by $0.01. The company also reported revenue of $12,870,000, missing estimates of $14,484,000 by $-1,614,000.
Stock price change since market close: +2.5%
You can see Quiver Quantitative's $ENTA stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ENANTA PHARMACEUTICALS Hedge Fund Activity
We have seen 52 institutional investors add shares of ENANTA PHARMACEUTICALS stock to their portfolio, and 74 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FARALLON CAPITAL MANAGEMENT, L.L.C. removed 1,468,202 shares (-60.7%) from their portfolio in Q3 2026, for an estimated $19,350,902
- BLACKROCK, INC. added 638,769 shares (+19.7%) to their portfolio in Q3 2026, for an estimated $8,418,975
- DEEP TRACK CAPITAL, LP removed 444,167 shares (-30.8%) from their portfolio in Q3 2026, for an estimated $5,854,121
- ADAR1 CAPITAL MANAGEMENT, LLC added 388,810 shares (+28.9%) to their portfolio in Q3 2026, for an estimated $5,124,515
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. removed 301,151 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $3,969,170
- SUMMITTX CAPITAL, L.P. added 257,702 shares (+inf%) to their portfolio in Q2 2026, for an estimated $3,757,295
- GEODE CAPITAL MANAGEMENT, LLC removed 142,040 shares (-18.3%) from their portfolio in Q3 2026, for an estimated $1,872,087
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
ENANTA PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $ENTA in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 09/23/2026
To track analyst ratings and price targets for ENANTA PHARMACEUTICALS, check out Quiver Quantitative's $ENTA forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.